Genomictree (228760) Fundamentals 2026 — Revenue Analysis | SniperIQ
Genomictree (228760) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩278.4B, trading at ₩11350.00 on the KOE. This SniperIQ fundamentals page covers Genomictree's valuation, profitability (net margin -209.8%), revenue (₩3.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Genomictree's market cap?
Genomictree (228760) has a market capitalization of approximately ₩278.4B, trading at ₩11350.00 on the KOE. Market cap moves with the live share price.
What is Genomictree's P/E ratio?
Genomictree's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Genomictree?
Genomictree runs a net profit margin of -209.8%, a gross margin of 1.2%, and an operating margin of -277.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Genomictree generate?
Genomictree reported revenue of ₩3.8B for fiscal year 2025, with net income of -₩9.0B and earnings per share (EPS) of -374.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Genomictree pay a dividend?
Genomictree does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Genomictree financially healthy?
Genomictree carries a debt-to-equity ratio of 0.00x and a current ratio of 56.88x, with a market beta of 2.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Genomictree a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Genomictree (228760) the key facts are: market cap ₩278.4B, revenue ₩3.8B, 52-week range 10010-33300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Genomictree's full fundamentals live
Get Genomictree's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.